BCL2L1 and cancer: Importantly, the use of a chemical inhibitor toolkit revealed a consistent senolytic response to the BCL-xL-specific BH3 mimetic A1331852, even in TIS cancer cells—both competent and incompetent—lacking enhanced mitochondrial priming.